Employees: 11-50
Founded date: 1971
Mentions in press and media 17
| Date | Title | Description |
| 17.10.2025 | Jupiter Endovascular: $40 Million Series B Raised For Transforming Fixation Technology | Jupiter Endovascular, a medical technology company pioneering a new class of endovascular procedures with its proprietary Transforming Fixation (TFX) platform, announced the close of an oversubscribed Series B financing round that exceeded ... |
| 14.10.2025 | Jupiter Endovascular Secures Over $40M, Advances Revolutionary Catheter Technology | Jupiter Endovascular secured over $40M in Series B funding. This capital fuels development and commercialization of its TFX catheter platform. This innovative system brings unprecedented stability and control to complex endovascular procedu... |
| 07.10.2025 | Jupiter Endovascular Closes Over $40M Series B Funding | Jupiter Endovascular, a Menlo Park, CA-based medical technology startup, closed its Series B funding at over $40M. The amount of the deal was not disclosed. The round was led by Sonder Capital, with participation from Senvest Management, LB... |
| 05.08.2024 | Senvest Capital Inc. annonce ses résultats pour le trimestre terminé le 30 juin 2024 | MONTRÉAL, 05 août 2024 (GLOBE NEWSWIRE) -- Senvest Capital Inc. a annoncé aujourd’hui un résultat net attribuable aux actionnaires ordinaires de (71,7 M$) ou (29,02 $) par action pour les trois mois terminés le 30 juin 2024. Pour la période... |
| 05.08.2024 | Senvest Capital Inc. Reports Results for the Second Quarter Ended June 30, 2024 | MONTREAL, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senvest Capital Inc. today reported a net loss attributable to common shareholders of ($71.7) million or ($29.02) per share for the three months ended June 30, 2024. This compares to net income at... |
| 05.08.2024 | Senvest Capital Inc. Reports Results for the Second Quarter Ended June 30, 2024 | MONTREAL, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senvest Capital Inc. today reported a net loss attributable to common shareholders of ($71.7) million or ($29.02) per share for the three months ended June 30, 2024. This compares to net income at... |
| 10.05.2024 | Senvest Capital Inc. annonce ses résultats pour le trimestre terminé le 31 mars 2024 | MONTRĖAL, 10 mai 2024 (GLOBE NEWSWIRE) -- Senvest Capital Inc. a annoncé aujourd’hui un résultat net attribuable aux actionnaires ordinaires de 52,3 M$ ou 21,17 $ par action pour les trois mois terminés le 31 mars 2024. Pour la période corr... |
| 10.05.2024 | Senvest Capital Inc. Reports Results for the First Quarter Ended March 31, 2024 | MONTREAL, May 10, 2024 (GLOBE NEWSWIRE) -- Senvest Capital Inc. today reported net income attributable to common shareholders of $52.3 million or $21.17 per share for the three months ended March 31, 2024. This compares to net income attrib... |
| 06.04.2024 | Biolinq Revolutionizes Glucose Monitoring with $58M Funding Boost | Biolinq, a San Diego-based healthcare technology company, secures $58M in funding to advance its innovative continuous glucose monitoring patch. Led by Alpha Wave Ventures, the funding will support completion of a pivotal clinical trial and... |
| 04.04.2024 | Biolinq Secures $58M to Advance Continuous Glucose Monitoring Patch | What You Should Know: – Biolinq, a provider of precision wearable biosensors for metabolic health secures $58M led by Alpha Wave Ventures. The round will include participation from Niterra’s corporate venture capital fund jointly operated w... |
Show more